SK4922002A3 - Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same - Google Patents
Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same Download PDFInfo
- Publication number
- SK4922002A3 SK4922002A3 SK492-2002A SK4922002A SK4922002A3 SK 4922002 A3 SK4922002 A3 SK 4922002A3 SK 4922002 A SK4922002 A SK 4922002A SK 4922002 A3 SK4922002 A3 SK 4922002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- disease
- imidazol
- formula
- treatment
- benzopyrano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Abstract
Description
Derivát imidazolu ako inhibítor fosfodiesterázy VII, jeho použitie a farmaceutický prostriedok, ktorý ho obsahujeAn imidazole derivative as a phosphodiesterase VII inhibitor, its use and a pharmaceutical composition containing it
Oblasť techniky ??Technique ??
Vynález sa týka derivátov imidazolu obecného vzorca IThe invention relates to imidazole derivatives of the formula I
kde znamenáwhere it means
R1 atóm vodíka, skupinu A, benzylovú, indan-5-ylovú ,R @ 1 is hydrogen, A, benzyl, indan-5-yl,
1,2,3,4-tetrahydronaftalén-5-ylovú, dibenzotiofén-2-yl-ovú alebo fenylovú, ktorá je nesubstituované alebo je monosubstituovaná, disubstituovaná alebo trisubstituovaná skupinou Hal, A, A-CO-NH, benzyloxyskupinou, alkoxyskupinou, skupinou COOH alebo COOA,1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothiophen-2-yl or phenyl which is unsubstituted or is monosubstituted, disubstituted or trisubstituted with Hal, A, A-CO-NH, benzyloxy, alkoxy, COOH or COOA
R2 atóm vodíka alebo skupinu A,R 2 is H or A,
X atóm kyslíka alebo síry,X is an oxygen or sulfur atom,
Hal atóm fluóru, chlóru, brómu alebo jódu,Hal is fluorine, chlorine, bromine or iodine,
A alkylovú skupinu s 1 až 6 atómami uhlíka, a jeho fyziologicky prijateľných solí a/nebo solvátov ako aj inhibítorov fosfodiesterázy VII.And an alkyl group having 1 to 6 carbon atoms, and physiologically acceptable salts and / or solvates thereof, as well as phosphodiesterase VII inhibitors.
Doterajší stav technikyBACKGROUND OF THE INVENTION
Benzopyranoimidazoly popísali napríklad M. Trkovnik a kol. (Org. Prep. Proced. Int. 19 (6), str. 450 až 455, 1987) alebo V.L. Savelev a kol. (Khin. Farm. Zh. 17 (6), str. 697 až 700, 1983) . Deriváty benzopyranoimidazolov popísal napríklad V.L. Savelev a kol. (Khim. Geterotsikl. Soedin. (4), str. 479 až 483, 1980).Benzopyranoimidazoles have been described, for example, by M. Trkovnik et al. (Org. Prep. Proced. Int. 19 (6): 450-455, 1987) or V.L. Savelev et al. (Khin. Farm. Zh. 17 (6): 697-700 (1983)). Benzopyranoimidazole derivatives have been described, for example, by V.L. Savelev et al. (Khim. Geterotsikl. Soedin. (4), pp. 479-483, 1980).
Úkolom vynálezu je vyvinúť nové zlúčeniny s hodnotnými vlastnosťami, zvlášť zlúčeniny, ktorých možno použiť k výrobe liečiv.SUMMARY OF THE INVENTION It is an object of the invention to provide novel compounds with valuable properties, in particular compounds which can be used for the manufacture of medicaments.
Podstata vynálezuSUMMARY OF THE INVENTION
Podstatou vynálezu sú zhora definované deriváty imidazolu obecného vzorca I a ich fyziologicky prijateíné soli alebo solváty ako aj inhibítory fosfodiesterázy VII.The present invention provides imidazole derivatives of the formula I as defined above and their physiologically acceptable salts or solvates as well as phosphodiesterase VII inhibitors.
Vynález sa ďalej týka použitia zlúčenín obecného vzorca I k výrobe liečiv k ošetrovaniu alergických porúch, astmy, chronickej bronchitídy, atopickej dermatitídy, lupienky a iných kožných ochorení, zápalový porúch, autoimunitných chorôb ako sú napríklad reumatoidná artritída, rozptýlená skleróza, Crohnova nemoc, diabetes mellitus alebo vredová kolitída, k ošetrovaniu osteoporózy, odhojenia transplantátov, chorobného chudnutia, rastu nádorov alebo nádorových metastáz, sepsy, porúch pamäti, aterosklerózy a AIDS.The invention further relates to the use of the compounds of formula I for the manufacture of a medicament for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory disorders, autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes. or ulcerative colitis, for the treatment of osteoporosis, transplant rejection, disease weight loss, tumor growth or tumor metastasis, sepsis, memory disorders, atherosclerosis and AIDS.
Zistilo sa s prekvapením, že zlúčeniny obecného vzorca I a ich soli majú velmi cenné farmakologické vlastnosti a pritom sa dobre znášajú. Obzvlášť vykazujú špecifickú inhibíciu na rolipram necitlivú cAMP fosfodiesterázu (PDE VII).It has been surprisingly found that the compounds of the formula I and their salts have very valuable pharmacological properties and are well tolerated. In particular, they exhibit specific inhibition of rolipram insensitive cAMP phosphodiesterase (PDE VII).
Biologická aktivita zlúčenín obecného vzorca I sa môže zisťovať spôsoby, ktoré popísať napríklad M.A, Giembycz a kol. (Br. J. Pharmacol. 118, str..1945 až 1958, 1996). Afinita zlúčenín pr aAMP fosfodiesterázu (PDE VII) sa zisťuje meraním ich hodnôt IC50 (koncentrácia inhibítoru potrebná k dosiahnutiu 50% inhibície enzýmovej aktivity).The biological activity of the compounds of formula I can be determined by methods described, for example, by M.A, Giembycz et al. (Br. J. Pharmacol. 118: 1945-1958, 1996). The affinity of compounds for αAMP phosphodiesterase (PDE VII) is determined by measuring their IC 50 values (inhibitor concentration required to achieve 50% inhibition of enzyme activity).
Stanovenie sa prevádza za použitia homogenizovaných neuroblastómových buniek SK-N-SH namiesto T-lymfocytov a CI930 sa používa k inhibícii PDE III. CI-930 je selektívny inhibítor PDE III (J. A. Bristol a kol., J. Med. Chem. 27(9), str. 1099 až 1101, 1984) .The assay is performed using homogenized SK-N-SH neuroblastoma cells instead of T cells and CI930 is used to inhibit PDE III. CI-930 is a selective PDE III inhibitor (J.A. Bristol et al., J. Med. Chem. 27 (9), pp. 1099-1101, 1984).
Zlúčenín obecného vzorca I je možno použiť k liečeniu astmatických chorôb. Antiastmatický účinok sa dá zistiť napríklad spôsobom podobným ako popísal T. Olson (Acta allergologica 26, str. 438 až 447, 1971).The compounds of formula I can be used to treat asthmatic diseases. The antiasthmatic effect can be determined, for example, in a manner similar to that described by T. Olson (Acta allergologica 26, 438-447, 1971).
Keďže aAMP inhibuje osteoklastové bunky a stimuluje bunky osteoblastové (S. Kasugai a kol., M 681 a K. Miyamoto, M 682 v Abstracts of the Ameriaan Sooiety for Bone and Minerál Research 18. výročné zhromaždenie 1996), môže byť zlúčenín obecného vzorca I použité k liečeniu osteoporózy.Since aAMP inhibits osteoclast cells and stimulates osteoblast cells (S. Kasugai et al., M 681 and K. Miyamoto, M 682 in Abstracts of the American Soil for Bone and Mineral Research 18th Annual Assembly 1996), the compounds of formula I may be used to treat osteoporosis.
Zlúčeniny ďalej vykazujú antagonistický účinok na produkciu TNFa (tumor necrosis factor) a hodia sa teda k liečeniu alergických a zápalových chorôb, autoimúnnych chorôb, ako sú napríklad reumatoidná artritída, roztrúsená skleróza,The compounds further show an antagonistic effect on the production of TNFα (tumor necrosis factor) and are thus suitable for the treatment of allergic and inflammatory diseases, autoimmune diseases such as rheumatoid arthritis, multiple sclerosis,
Crohnova nemoc, diabetes mellitus alebo vredovité kolitídy, k odhojeniu transplantátov, k ošetrovaniu chorobného chudnutia a sepsy.Crohn's disease, diabetes mellitus or ulcerative colitis, for graft rejection, for the treatment of disease weight loss and sepsis.
Protizápalové pôsobenie zlúčenín obecného vzorce I a ich účinnosť pri liečeniu napríklad autoimúnnych chorôb, ako je roztrúsená skleróza a reumatoidná artritída sa môže zisťovať spôsoby, ktoré popísali N.Sommer a kol. (NátureThe anti-inflammatory activity of the compounds of formula I and their efficacy in the treatment of, for example, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis can be ascertained by the methods described by N.Sommer et al. (Nature
Medicíne 1, str. 244 až 248, 1995) alebo L. Sekut a kol. (Clin. Exp. Immuno1. 100, str. 126 až 132, 1995).Medicine 1, p. 244-248 (1995) or L. Sekut et al. (Clin. Exp. Immunol. 100: 126-132, 1995).
Zlúčenín možno použiť k liečeniu chorobnému vysileniu (kachexie). Účinok proti chorobnému vysileniu možno testovať na modeloch kachexie závislých na TNF (P. Costelli a kol., J. Clin. Invest 95, od str. 2367, 1995; J.M. Arailes a kol., Med. Res. Rev. 17, od str. 477, 1997) .The compounds may be used to treat diseased debilitating (cachexia). The efficacy against disease exhaustion can be tested in TNF-dependent cachexia models (P. Costelli et al., J. Clin. Invest 95, from p. 2367, 1995; JM Arailes et al., Med. Res. Rev. 17, p. 477 (1997).
Inhibítory PDE VII môžu tiež inhibovať rast nádorových buniek a zídu sa preto k nádorovej terapii (pre inhibítory PDE IV, D. Marko a kol., Celí Biochem. Biophys, 28, od str. 75, 1998).PDE VII inhibitors may also inhibit the growth of tumor cells and will therefore go on to tumor therapy (for PDE IV inhibitors, D. Marko et al., Cell Biochem. Biophys, 28, p. 75, 1998).
Ďalej ich možno použiť k liečeniu sepsy a k liečeniu porúch pamäti, aterosklerôzy, atopickej dermatitídy a AIDS rovnako ako k liečeniu chorôb závislých na T-bunkách (L. Li a kol. Science 283, str. 848 až 851, 1999).Further, they can be used to treat sepsis and to treat memory disorders, atherosclerosis, atopic dermatitis and AIDS as well as to treat T-cell dependent diseases (L. Li et al. Science 283, 848-851, 1999).
Vynález sa ďalej týka použitia inhibítorov fosfodiesterázy YII k výrobe liečiv k liečeniu alergických porúch, astmy, chronickej bronchitídy, atopickej dermatitídy, lupienky a iných kožných ochorení, zápalových porúch, autoimunitných chorôb ako sú napríklad reumatoidná artritída, rozptýlená skleróza, Crohnova choroba, diabetes mellitus alebo vredová kolitída, osteoporóza, odhojenie transplantátov, chorobné chudnutie, rast nádorov alebo nádorové metastázy, sepsy, poruchy pamäti, ateroskleróza a AIDS.The invention further relates to the use of phosphodiesterase YII inhibitors for the manufacture of a medicament for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory disorders, autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, diabetes mellitus or Crohn's disease. ulcerative colitis, osteoporosis, transplant rejection, disease weight loss, tumor growth or tumor metastasis, sepsis, memory disorders, atherosclerosis and AIDS.
Zlúčeniny obecného vzorca I sa môžu používať ako farmaceutický aktívne zložky pre inhibíciu PDE VII v humánnej a vo veterinárnej medicíne.The compounds of formula I can be used as pharmaceutical active ingredients for inhibiting PDE VII in human and veterinary medicine.
V obecnom vzorci I znamená A alkylovú skupinu s 1, 2, 3, 4, 5 alebo 6 atómami uhlíka a s výhodou skupinu metylovú, etylovú alebo propylovú, tiež s výhodou skupinu izopropylovú, butylovú, izo-butylovú, sek-butylovú, terc-butylovú, ale tiež skupinu n-pentylovú, neopentylovú, izopentylovú alebo hexylovú. A znamená tiež skupinu cykloalkylovú, napríklad cyklohexylovou skupinu.In formula (I), A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and preferably methyl, ethyl or propyl, also preferably isopropyl, butyl, isobutyl, sec-butyl, tert-butyl but also an n-pentyl, neopentyl, isopentyl or hexyl group. A also represents a cycloalkyl group, for example a cyclohexyl group.
Alkoxyskupinou sa mieni s výhodou metoxyskupina, etoxyskupina, propoxyskupina alebo butoxyskupina.Alkoxy is preferably methoxy, ethoxy, propoxy or butoxy.
Symbol Hai znamená s výhodou atóm fluóru alebo chlóru.The symbol Hai is preferably a fluorine or chlorine atom.
Skupinou A-CO-NH je s výhodou acetamidoskupina.The A-CO-NH group is preferably acetamido.
Zásada obecného vzorca I sa môže kyselinou prevádzať na príslušnú adičnú sol s kyselinou, napríklad reakciou ekvivalentného množstva zásady a kyseliny v inertnom rozpúšťadle, ako je napríklad etanol a následným odparením rozpúšťadla. Pre túto reakciu prichádzajú v úvahu zvlášť kyseliny, ktoré poskytujú fyziologicky prijatelné soli. Môže sa používať anorganických kyselín, ako sú kyselina sírová, dusičná, halogenovodíkové kyseliny, ako chlorovodíková alebo bromovodíková, fosforečné kyseliny, ako kyselina ortofosforečná, sulfamínová kyselina a organické kyseliny, zvlášť alifatické, alicyklioké, aralifatické, aromatické alebo heteroayklické jednosýtne alebo niekoľkosýtne karboxylové, sulfónové alebo sírové kyseliny, ako sú kyselina mravčia, octová, propiónová, jantárová, pimelová, jablčná, citrónová, pivalová, dietylootová, malónová, fumarová, maleínová, mliečna, vínna, glukónová, askorbová, nikotínová, izonikotínová, metánsulfónová, etánsulfónová, etándisulfónová, 2-hydroxyetánsulfónová, benzénsulfónová, p-toluénsulfónová, naftalénmonosulfónová a naftaléndisulfónová a laurylsírová kyselina. Solí s fyziologicky nevhodnými kyselinami, napríklad pikrátov, sa môže používať k izolácii a/alebo k čisteniu zlúčenín obecného vzorca I.The base of formula (I) can be converted into the appropriate acid addition salt by acid, for example by reaction of an equivalent amount of base and acid in an inert solvent such as ethanol and subsequent evaporation of the solvent. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Inorganic acids such as sulfuric, nitric, hydrohalic acids such as hydrochloric or hydrobromic acids, phosphoric acids such as orthophosphoric acid, sulfamic acid and organic acids may be used, especially aliphatic, alicyclic, araliphatic, aromatic or heteroaryl monohydric or polybasic carboxylic, sulfonic acids or sulfuric acids such as formic, acetic, propionic, succinic, pimelic, malic, citric, pivalic, diethylootic, malonic, fumaric, maleic, lactic, tartaric, gluconic, ascorbic, nicotinic, isonicotinic, ethanesulfonic, methanesulfonic, methanesulfonic, -hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene monosulfonic acid, naphthalenedisulfonic acid and lauryl sulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used to isolate and / or purify the compounds of formula I.
Vynález sa ďalej týka farmaceutických prostriedkov obsahujúcich ako aj aspoň jeden inhibítor fosfodiesterázy VII zlúčeninu obecného vzorca I alebo jej fyziologicky prijateľnú sol a/alebo solvát pre ošetrovanie alergických porúch, astmy, chronickej bronchitídy, atopickej dermatitídy, lupienky a iných kožných ochorení, zápalových porúch, autoimunitných chorôb, ako sú napríklad reumatoidná artritída, rozptýlená skleróza, Crohnova choroba, diabetes mellitus alebo vredovitá colitída, k ošetrovaniu osteoporózy, odhojovania transplantátov, chorobného schudnutia, rastu nádorov alebo nádorových metastáz, sepsy, porúch pamäti, aterosklerózy aThe invention further relates to pharmaceutical compositions comprising as well as at least one phosphodiesterase VII inhibitor a compound of the formula I or a physiologically acceptable salt and / or solvate thereof for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory disorders, autoimmune diseases. diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, for the treatment of osteoporosis, transplant rejection, disease loss, tumor growth or tumor metastasis, sepsis, memory disorders, atherosclerosis and
AIDS.AIDS.
Zlúčeniny obecného vzorca I podía vynálezu sa spravidla podávajú v dávke približne 1 až 500 mg, zvlášť 5 až 100 mg na dávkovaciu jednotku. Denná dávka je s výhodou približne 0,02 až 10 mg/kg telesnej hmotnosti. Špecifická dávka pre každého jednotlivého jedinca závisí od najrôznejších faktorov, napríklad na účinnosti určitej použitej zlúčeniny, na veku, telesnej hmotnosti, všeobecnom zdravotnom stave, pohlaviu, strave, na okamžiku a ceste podania, na rýchlosti vylučovania, na kombinácii liečiv a na závažnosti určitého ochorenia. Výhodné je orálne podanie.The compounds of the formula I according to the invention are generally administered in a dose of approximately 1 to 500 mg, in particular 5 to 100 mg per dosage unit. The daily dose is preferably about 0.02 to 10 mg / kg body weight. The specific dose for each individual depends on a variety of factors, such as the efficacy of a particular compound used, age, body weight, general health, sex, diet, time and route of administration, excretion rate, drug combination and severity of the disease. . Oral administration is preferred.
Farmaceutických prostriedkov sa môže používať ako aj liečiv v humánnej a vo veterinárnej medicíne. Ako aj nosiče prichádzajú v úvahu anorganické alebo organické látky, ktoré sú vhodné pre enterálne (napríklad orálne) alebo pre parenterálne alebo topické podávanie alebo pre podávanie vo forme inhalačných sprejov a ktoré nereagujú zo zlúčeninami obecného vzorca I, ako sú napríklad voda, rastlinné oleje, benzylalkoholy, alkylénglykoly, polyetylénglykoly, glyceríntriacetát, želatína, uhľohydráty, ako laktóza alebo škroby, stearát horečnatý, mastenec a vazelína. Pre orálne použitie sa hodia zvlášť tablety, pilulky, dražé, kapsuly, prášky, granuláty, sirupy, suspenzie alebo kvapky, pre rektálne použitie čapíky, pre parenterálne použitie roztoky, zvlášť olejové alebo vodné roztoky, ďalej suspenzie, emulzie alebo implantáty, pre topické použitie masti, krémy alebo pudry. Zlúčeniny podía vynálezu sa tiež môžu lyofilizovať a získaných lyofilizátov sa môže napríklad používať pre prípravu vstrekovatelných prostriedkov. Prostriedky sa môžu sterilovať a/nebo môžu obsahovať pomocné látky, ako sú klzné činidlá, konzervačné, stabilizačné činidlá a/alebo zmáčadlá, emulgátory, soli k ovplyvneniu osmotického tlaku, pufre, farbivá, chuťové prísady alebo ešte jednu ďalšiu alebo ešte niekolko ďalších účinných látok, ako sú napríklad vitamíny.The pharmaceutical compositions can be used as well as medicaments in human and veterinary medicine. Suitable carriers are inorganic or organic substances which are suitable for enteral (e.g. oral) or parenteral or topical administration or for administration in the form of inhalation sprays and which do not react with compounds of formula I, such as water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starches, magnesium stearate, talc and petrolatum. Especially suitable for oral use are tablets, pills, dragees, capsules, powders, granules, syrups, suspensions or drops, suppositories for rectal use, solutions for parenteral use, especially oily or aqueous solutions, further suspensions, emulsions or implants, for topical use ointments, creams or powders. The compounds of the invention may also be lyophilized and the resulting lyophilisates used, for example, for the preparation of injectables. The compositions may be sterilized and / or may contain adjuvants such as glidants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffers, coloring agents, flavoring agents or one or more other active ingredients. such as vitamins.
Vynález sa zvlášť týka zlúčenín obecného vzorca I uvedených v nasledujúcich príkladoch a ich fyziologicky prijateľných solí alebo solvátov ako aj PDE VII inhibítorov a ich použitia pre výrobu farmaceutických prostriedkov pre ošetrovanie alergických porúch, astmy, chronickej bronchitídy, atopickej dermatitídy, lupienky a iných kožných ochorení, zápalových porúch, autoimunitných chorôb, ako sú napríklad reumatoidná artritída, rozptýlená skleróza, Crohnova choroba, diabetes mellitus alebo vredová colitída, k ošetrovaniu osteoporózy, odhojovaniu transplantátov, chorobného schudnutia, rastu nádorov alebo nádorových metastáz, sepsy, porúch pamäti, aterosklerózy a AIDS.In particular, the invention relates to the compounds of the formula I shown in the following examples and their physiologically acceptable salts or solvates as well as PDE VII inhibitors and their use for the manufacture of pharmaceutical compositions for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases. inflammatory disorders, autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, for the treatment of osteoporosis, graft rejection, disease weight loss, tumor growth or tumor metastasis, and sepsis, sepsis, sepsis, sepsis.
Vynález objasňujú, nijako však neobmedzujú nasledujúce príklady.The invention is illustrated by the following examples.
Príklady prevedenia vynálezuExamples
1-Fenyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-phenyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one
1-benzyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-benzyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one
1-cyklohexyl [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-Cyclohexyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-cyklopentyl [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-Cyclopentyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-butyl [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-Butyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-izopropyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-isopropyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one
1-propyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-propyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one
1-etyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-ethyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one
1- metyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1-Methyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
2- metyl [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,2-Methyl [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-fenyl [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,1-phenyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
1-benzyl[1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,1-benzyl [1] benzothiopyran [3,4-d] imidazol-4- (1H) -one
1-cyklohexyl [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón, 1-cyklopentyl [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón, 1-butyl [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,1-Cyclohexyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one, 1-cyclopentyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one, 1- butyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
1-izopropyl[l]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,1-isopropyl [l] benzothiopyran [3,4-d] imidazol-4- (1H) -one
1-propyl[1]benzotiopyrano[3, 4-d]imidazol-4-(1H)-ón,1-propyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
1-etyl[1]benzotiopyrano[3, 4-d]imidazol-4-(1H)-ón,1-Ethyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
1- metyl[1]benzotiopyrano[3,4-d]imidazol-4-(1H), [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,1-Methyl [1] benzothiopyrano [3,4-d] imidazole-4- (1H), [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
2- metyl [1]benzotiopyrano[3,4-d]imidazol-4-(1H)-ón,2-Methyl [1] benzothiopyrano [3,4-d] imidazol-4- (1H) -one,
1- (2-chlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (2-chlorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1 H) -one,
1- (4-metylfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (4-Methylphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-(4-fluórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (4-fluorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1 H) -one,
1-(2, 4-dimetylfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(3-chlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (2,4-Dimethylphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (3-chlorophenyl) [1] benzopyrano [3,4-d] imidazole- 4 (1H) -one
1-(2,4-dichlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(2,5-dichlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(4-acetamidofenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(2-fluórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (2,4-Dichlorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (2,5-dichlorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (4-acetamidophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (2-fluorophenyl) [1] benzopyrano [ 3,4-d] imidazol-4- (1H) -one
1-(3-fluórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (3-fluorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1 H) -one,
1-(2-benzyloxyfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(2,6-dimetylfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(indan-5-yl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (2-Benzyloxyphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (2,6-dimethylphenyl) [1] benzopyrano [3,4-d] imidazole- 4- (1H) -one, 1- (indan-5-yl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-(2-metoxyfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (2-Methoxyphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-(2, 3-dimetylfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(2,3-dichlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(3-chlór-4-metylfenyl)[1]benzopyrano[3,4-d]imidazol-4-(1H)ón,1- (2,3-Dimethylphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (2,3-dichlorophenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (3-chloro-4-methylphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one,
1-(2,5-dimetylfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(4-chlórfenyl) [1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(1,2,3,4-tetrahydroneftalén-5-yl) [1]benzopyrano[3, 4d]imidazol-4-(1H)-ón,1- (2,5-dimethylphenyl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (4-chlorophenyl) [1] benzopyrano [3,4-d] imidazole- 4- (1H) -one, 1- (1,2,3,4-tetrahydronephthalen-5-yl) [1] benzopyrano [3,4d] imidazol-4- (1H) -one,
1-(dibenzotiofén-2-yl)[1]benzopyrano[3,4-d]imidazol-4-(1H)-ón, 1-(3-metoxyfenyl) 11]benzopyrano[3,4-d]imidazol-4-(1H)-ón,1- (dibenzothiophen-2-yl) [1] benzopyrano [3,4-d] imidazol-4- (1H) -one, 1- (3-methoxyphenyl) 11] benzopyrano [3,4-d] imidazole-4 - (1 H) -one
1-(4-karboxy-2-metylfenyl)[1]benzopyrano[3,4-d]imidazol-4(1H)-ón,1- (4-carboxy-2-methylphenyl) [1] benzopyrano [3,4-d] imidazole-4 (1H) -one
Nasledujúce príklady objasňujú farmaceutické prostriedky:The following examples illustrate pharmaceutical compositions:
Príklad AExample A
Injekčné ampulkyInjection ampoules
Roztok 100 g zlúčeniny obecného vzorce I ako inhibítora fosfodiesterázy VII a 5 g dinátriumhydrogenfosfátu v 3 1 dva razy destilovanej vody sa nastaví 2n kyselinou chlorovodíkovou na hodnotu pH 6,5, sterilné sa sfiltruje a plní sa do injekčných ampuliek, lyofilizuje sa za sterilných podmienok a sterilné sa ampulky uzatvoria. Každá injekčná ampulka obsahuje 5 mg účinnej látky.A solution of 100 g of a phosphodiesterase VII inhibitor of formula I and 5 g of disodium hydrogen phosphate in 3 L of two times distilled water is adjusted to pH 6.5 with 2N hydrochloric acid, sterile filtered and filled into injection vials, lyophilized under sterile conditions and the sterile vials are sealed. Each vial contains 5 mg of active ingredient.
Príklad BExample B
Čapíkysuppository
Roztaví sa zmes 20 g zlúčeniny obecného vzorca I ako inhibítora fosfodiesterázy VII sa 100 g sójového lecitínu a 1400 g kakaového masla, vleje sa do formičiek a nechá sa vychladnúť. Každý čapík obsahuje 20 mg účinnej látky.A mixture of 20 g of a phosphodiesterase VII inhibitor of formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
Príklad CExample C
Roztoksolution
Pripraví sa roztok 1 g zlúčeniny obecného vzorca I ako inhibítora fosfodiesterázy VII, 9,38 g dihydrátu nátriumdihydrogenfosfátu, 28,48 g dinátriumhydrogenfosfátu s 12 molekulami vody a 0,1 g benzälkóniumchloridu v 940 ml dvakrát destilovanej vody. Hodnota pH roztoku sa upraví na 6,8, doplní sa na jeden liter a steriluje sa ožiarením. Tohto roztoku je možno používať ako očných kvapiek.A solution of 1 g of a compound of formula I as a phosphodiesterase VII inhibitor, 9.38 g of sodium dihydrogen phosphate dihydrate, 28.48 g of dihydrogen phosphate with 12 water molecules and 0.1 g of benzalkonium chloride in 940 ml of double distilled water is prepared. The pH of the solution is adjusted to 6.8, made up to 1 liter and sterilized by irradiation. This solution can be used as eye drops.
Príklad D.Example D.
Masťointment
Zmieša sa 500 mg zlúčeniny látky obecného vzorca I ako inhibítora fosfodiesterázy VII s 99,5 g vazelíny za aseptických podmienok.500 mg of a phosphodiesterase VII inhibitor compound of formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
Príklad EExample E
Tabletytablets
Zo zmesi 1 kg zlúčeniny obecného vzorca I ako inhibítora fosfodiesterázy VII, 4 kg laktózy, 1,2 kg zemiakového škrobu, 0,2 kg mastenca a 0,1 kg stearátu horečnatého sa obvyklým spôsobom vylisujú tablety, tak, že každá tableta obsahuje 10 mg účinnej látky.From a mixture of 1 kg of a compound of formula I as a phosphodiesterase VII inhibitor, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate, tablets are compressed in a conventional manner such that each tablet contains 10 mg of the active substance.
Príklad FExample F
Dražédragee
Obdobne ako podía príkladu E sa vylisujú tablety, ktoré sa potom obvyklým spôsobom potiahnú povlakom zo sacharózy, zemiakového škrobu, mastenca, tragantu a farbiva.Analogously to Example E, tablets are compressed and then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
Príklad GExample G
KapsulyThe capsules
O sebe známym spôsobom sa plnia do kapsúl z tvrdej želatíny 2 kg zlúčeniny obecného vzorca I ako inhibítora fosfodiesterázy VII tak, že každá kapsula obsahuje 20 mg účinnej látky.In a manner known per se, 2 kg of a compound of formula I as a phosphodiesterase VII inhibitor are filled into hard gelatin capsules such that each capsule contains 20 mg of the active ingredient.
Príklad HExample H
Ampulyampoules
Roztok 1 kg zlúčeniny obecného vzorca I ako inhibítora fosfodiesterázy VII v 60 1 dvakrát destilovanej vody sa sterilné sfiltruje a plní sa do ampúl, lyofilizuje sa za sterilných podmienok a sterilné sa ampuly uzatvoria. Každá ampula obsahuje 10 mg účinnej látky.A solution of 1 kg of a phosphodiesterase VII inhibitor compound of formula I in 60 L of double-distilled water is sterile filtered and filled into ampoules, lyophilized under sterile conditions and the ampoules sealed. Each ampoule contains 10 mg of active ingredient.
Príklad IExample I
Inhalačný sprejInhalation spray
Rozpustí sa 14 g zlúčeniny obecného vzorca I ako inhĺbitora fosfodiesterázy VII v 10 I izotonického roztoku chloridu sodného a plní sa do bežných obchodných nádob pre striekanie s pumpovým mechanizmom. Roztok sa môže striekať do úst alebo do nosu. Každý strik (približne 0,1 ml) odpovedá dávke približne 0,14 mg.Dissolve 14 g of a compound of formula I as a phosphodiesterase VII inhibitor in 10 l of isotonic sodium chloride solution and fill into conventional commercial spray canisters with a pump mechanism. The solution may be sprayed into the mouth or nose. Each spray (about 0.1 ml) corresponds to a dose of about 0.14 mg.
Priemyslová využitelnosťIndustrial Applicability
Derivát imidazolu a jeho farmaceutický prijatelné soli a/alebo solváty ako inhibítory fosfodiesterázy VII pre výrobu farmaceutických prostriedkov.The imidazole derivative and pharmaceutically acceptable salts and / or solvates thereof as phosphodiesterase VII inhibitors for the manufacture of pharmaceutical compositions.
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19950647A DE19950647A1 (en) | 1999-10-21 | 1999-10-21 | Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS |
PCT/EP2000/009926 WO2001029049A2 (en) | 1999-10-21 | 2000-10-10 | Imidazole derivatives as phosphodiesterase vii inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SK4922002A3 true SK4922002A3 (en) | 2002-09-10 |
Family
ID=7926352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK492-2002A SK4922002A3 (en) | 1999-10-21 | 2000-10-10 | Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1222193B1 (en) |
JP (1) | JP2003512381A (en) |
KR (1) | KR20020060201A (en) |
CN (1) | CN1382146A (en) |
AR (1) | AR026198A1 (en) |
AT (1) | ATE247121T1 (en) |
AU (1) | AU780788B2 (en) |
BR (1) | BR0014922A (en) |
CA (1) | CA2388314C (en) |
CZ (1) | CZ293751B6 (en) |
DE (2) | DE19950647A1 (en) |
DK (1) | DK1222193T3 (en) |
ES (1) | ES2200957T3 (en) |
HU (1) | HUP0203139A3 (en) |
MX (1) | MXPA02003952A (en) |
NO (1) | NO20021846L (en) |
PL (1) | PL355020A1 (en) |
PT (1) | PT1222193E (en) |
RU (1) | RU2259199C2 (en) |
SK (1) | SK4922002A3 (en) |
WO (1) | WO2001029049A2 (en) |
ZA (1) | ZA200203995B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2439784C (en) | 2001-12-13 | 2010-11-02 | Daiichi Suntory Pharma Co., Ltd. | Pyrazolopyrimidinone derivatives having pde7 inhibiting action |
DE10163991A1 (en) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
JP2006219374A (en) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Imidazotriazinone derivative having pde 7 inhibition |
JP2006219373A (en) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pyridinylpyrazolopyrimidinone derivative having pde 7 inhibition |
MX2007000214A (en) | 2004-07-01 | 2007-05-10 | Asubio Pharma Co Ltd | Thienopyrazole derivative having pde7 inhibitory activity. |
MX2009010450A (en) | 2007-03-27 | 2009-11-23 | Omeros Corp | The use of pde7 inhibitors for the treatment of movement disorders. |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
KR20220047894A (en) | 2010-11-08 | 2022-04-19 | 오메로스 코포레이션 | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4305954A (en) * | 1981-02-11 | 1981-12-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones |
CA2346937A1 (en) * | 1998-10-15 | 2000-04-27 | Per O. G. Arkhammar | Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
WO2000068230A1 (en) * | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
-
1999
- 1999-10-21 DE DE19950647A patent/DE19950647A1/en not_active Withdrawn
-
2000
- 2000-10-10 RU RU2002111413/15A patent/RU2259199C2/en not_active IP Right Cessation
- 2000-10-10 ES ES00972714T patent/ES2200957T3/en not_active Expired - Lifetime
- 2000-10-10 AT AT00972714T patent/ATE247121T1/en not_active IP Right Cessation
- 2000-10-10 CZ CZ20021251A patent/CZ293751B6/en not_active IP Right Cessation
- 2000-10-10 KR KR1020027004903A patent/KR20020060201A/en not_active Application Discontinuation
- 2000-10-10 PL PL00355020A patent/PL355020A1/en unknown
- 2000-10-10 MX MXPA02003952A patent/MXPA02003952A/en unknown
- 2000-10-10 DE DE50003309T patent/DE50003309D1/en not_active Expired - Lifetime
- 2000-10-10 WO PCT/EP2000/009926 patent/WO2001029049A2/en active IP Right Grant
- 2000-10-10 DK DK00972714T patent/DK1222193T3/en active
- 2000-10-10 JP JP2001531847A patent/JP2003512381A/en active Pending
- 2000-10-10 BR BR0014922-5A patent/BR0014922A/en not_active IP Right Cessation
- 2000-10-10 AU AU11356/01A patent/AU780788B2/en not_active Ceased
- 2000-10-10 EP EP00972714A patent/EP1222193B1/en not_active Expired - Lifetime
- 2000-10-10 SK SK492-2002A patent/SK4922002A3/en unknown
- 2000-10-10 PT PT00972714T patent/PT1222193E/en unknown
- 2000-10-10 HU HU0203139A patent/HUP0203139A3/en unknown
- 2000-10-10 CA CA002388314A patent/CA2388314C/en not_active Expired - Fee Related
- 2000-10-10 CN CN00814402A patent/CN1382146A/en active Pending
- 2000-10-20 AR ARP000105542A patent/AR026198A1/en unknown
-
2002
- 2002-04-19 NO NO20021846A patent/NO20021846L/en not_active Application Discontinuation
- 2002-05-20 ZA ZA200203995A patent/ZA200203995B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1222193A2 (en) | 2002-07-17 |
ES2200957T3 (en) | 2004-03-16 |
NO20021846D0 (en) | 2002-04-19 |
DE19950647A1 (en) | 2001-04-26 |
DE50003309D1 (en) | 2003-09-18 |
PL355020A1 (en) | 2004-03-22 |
RU2259199C2 (en) | 2005-08-27 |
CA2388314C (en) | 2009-06-16 |
BR0014922A (en) | 2002-06-11 |
DK1222193T3 (en) | 2003-12-01 |
NO20021846L (en) | 2002-04-19 |
AU780788B2 (en) | 2005-04-14 |
HUP0203139A2 (en) | 2003-01-28 |
PT1222193E (en) | 2003-12-31 |
MXPA02003952A (en) | 2004-09-06 |
HUP0203139A3 (en) | 2004-12-28 |
CA2388314A1 (en) | 2001-04-26 |
CZ293751B6 (en) | 2004-07-14 |
CN1382146A (en) | 2002-11-27 |
KR20020060201A (en) | 2002-07-16 |
JP2003512381A (en) | 2003-04-02 |
ATE247121T1 (en) | 2003-08-15 |
ZA200203995B (en) | 2003-10-29 |
EP1222193B1 (en) | 2003-08-13 |
WO2001029049A3 (en) | 2001-11-01 |
AR026198A1 (en) | 2003-01-29 |
WO2001029049A2 (en) | 2001-04-26 |
CZ20021251A3 (en) | 2002-07-17 |
AU1135601A (en) | 2001-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6737436B1 (en) | Pyrrole derivatives as phosphodiesterase VII inhibitors | |
EP1226143B1 (en) | Imidazopyridine derivatives used as phosphodiesterase vii inhibitors | |
US7491742B2 (en) | Imidazole derivatives as phosphodiesterase VII inhibitors | |
EP1036078B1 (en) | Thienopyrimidines | |
EP1228073B1 (en) | Imidazole compounds used as phosphodiesterase vii inhibitors | |
DE19826841A1 (en) | Arylalkanoylpyridazines | |
EP1084125B1 (en) | Condensed thienopyrimidines with phosphodiesterase-v inhibiting action | |
SK4922002A3 (en) | Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same | |
US6531498B1 (en) | Isoxazole derivatives to be used as phosphodiesterase VII inhibitors | |
DE19915365A1 (en) | Tetrahydropyridazine derivatives |